✦ LIBER ✦

How controversial are surrogate endpoints?

✍ Scribed by Mamelok, Richard

Book ID: 109901775
Publisher: Nature Publishing Group
Year: 1994
Tongue: English
Weight: 328 KB
Volume: 12
Category: Article
ISSN: 1087-0156
DOI: 10.1038/nbt0294-134

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Are commercial immunoassay kits satisfac

Are commercial immunoassay kits satisfactory for measuring pharmacodynamic and surrogate endpoints?

✍ I. T. James 📂 Article 📅 2000 🏛 Springer 🌐 English ⚖ 149 KB

Screening for ovarian cancer: What are t

Screening for ovarian cancer: What are the optimal surrogate endpoints for clinical trials?

✍ Beth Y. Karlan 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 634 KB

The inability to identify relevant markers for presymptomatic screening in early stage or "preinvasive" ovarian cancer has plagued investigators and clinicians facing the problems of early detection. The characteristic late stage of disease at initial presentation has hindered our understanding of t